Smith, Moore & Co’s GSK GSK Stock Holding History

Smith, Moore & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,826	Closed	-$426K	–	388
2022 Q2	$426K	Sell	7,826 -640	-8%	-$35.3K	0.07%	241
2022 Q1	$461K	Sell	8,466 -384	-4%	-$20.9K	0.06%	255
2021 Q4	$488K	Buy	8,850 +432	+5%	+$22.5K	0.07%	242
2021 Q3	$402K	Sell	8,418 -32	-0.4%	-$1.61K	0.06%	261
2021 Q2	$421K	Buy	8,450 +1,104	+15%	+$53K	0.06%	257
2021 Q1	$328K	Buy	7,346 +22	+0.3%	+$999	0.05%	279
2020 Q4	$337K	Sell	7,324 -1,986	-21%	-$91.2K	0.06%	251
2020 Q3	$438K	Buy	9,310 +1,616	+21%	+$81K	0.09%	211
2020 Q2	$392K	Sell	7,694 -891	-10%	-$45.7K	0.09%	209
2020 Q1	$407K	Buy	8,585 +2,468	+40%	+$132K	0.11%	172
2019 Q4	$359K	Sell	6,117 -2,020	-25%	-$112K	0.07%	229
2019 Q3	$434K	Sell	8,137 -978	-11%	-$50.3K	0.1%	199
2019 Q2	$456K	Buy	9,115 +4	+0%	+$201	0.1%	194
2019 Q1	$476K	Buy	9,111 +1,076	+13%	+$53.8K	0.11%	178
2018 Q4	$384K	Sell	8,035 -2,054	-20%	-$101K	0.1%	196
2018 Q3	$507K	Buy	10,089 +247	+3%	+$12.5K	0.12%	166
2018 Q2	$496K	Buy	9,842 +1,765	+22%	+$88.9K	0.12%	156
2018 Q1	$394K	Sell	8,077 -1,881	-19%	-$87.6K	0.11%	188
2017 Q4	$442K	Buy	9,958 +372	+4%	+$17.2K	0.12%	173
2017 Q3	$486K	Buy	9,586 +2,065	+27%	+$105K	0.14%	143
2017 Q2	$405K	Buy	7,521 +164	+2%	+$8.74K	0.14%	144
2017 Q1	$388K	Buy	7,357 +213	+3%	+$10.8K	0.14%	144
2016 Q4	$344K	Buy	7,144 +209	+3%	+$10.3K	0.13%	154
2016 Q3	$374K	Buy	6,935 +162	+2%	+$8.88K	0.15%	131
2016 Q2	$367K	Buy	+6,773	New	+$357K	0.15%	132

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Smith, Moore & Co's GSK Position: Q3 2022 in Review

Smith, Moore & Co sold out of GSK (GSK) in Q3 2022, closing a stake of 7,826 shares — an estimated $426K sold.

Smith, Moore & Co first reported a position in GSK in Q2 2016 and held it in 25 quarters. The position peaked at $507K in Q3 2018. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Smith, Moore & Co reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Smith, Moore & Co sold 7,826 GSK shares in Q3 2022, an estimated $426K.
Smith, Moore & Co first reported a position in GSK in Q2 2016 and held it in 25 quarters.
Smith, Moore & Co's GSK position peaked at $507K in Q3 2018.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Smith, Moore & Co's 13F filing for Q3 2022, filed 14 Nov 2022.